Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Chimerix Inc.

Start price
Target price
Perf. (%)
€1.19
24.06.23
€3.00
31.03.26
-27.97%
18:13

Could be very worthwhile Investment >20% year
buy
Intellia Therapeutics Inc

Start price
Target price
Perf. (%)
€38.49
24.06.23
€50.00
31.03.26
-48.39%
18:32

Could be very worthwhile Investment >20% year
buy
Cymabay Therapeutics Inc

Start price
Target price
Perf. (%)
€6.95
24.06.23
€20.00
31.03.26
101.44%
01.10.23

Could be very worthwhile Investment >20% year
buy
Geron Corp.

Start price
Target price
Perf. (%)
€2.88
24.06.23
€4.00
30.04.26
-27.18%
03.03.24

Could be very worthwhile Investment >20% year
buy
Heron Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.12
24.06.23
€2.30
31.03.26
51.79%
08.01.24

Could be very worthwhile Investment >20% year
buy
Immunogen Inc.

Start price
Target price
Perf. (%)
€18.52
24.06.23
€30.00
31.12.25
-5.02%
30.07.23

Could be very worthwhile Investment >20% year
buy
Immutep LTD ADR

Start price
Target price
Perf. (%)
€1.75
24.06.23
€4.00
31.12.25
25.71%
15:54

Could be very worthwhile Investment >20% year
buy
Intra-Cellular Therapies Inc.

Start price
Target price
Perf. (%)
€58.60
24.06.23
€90.00
30.06.26
18.43%
19.02.24

Could be very worthwhile Investment >20% year
buy
Krystal Biotech

Start price
Target price
Perf. (%)
€105.00
24.06.23
€200.00
30.04.26
68.86%
09:55

Could be very worthwhile Investment >20% year
buy
Madrigal Pharmaceuticals inc.

Start price
Target price
Perf. (%)
€214.90
24.06.23
€380.00
31.05.26
3.30%
12:16

Could be very worthwhile Investment >20% year
buy
Prothena Corp. plc

Start price
Target price
Perf. (%)
€62.00
24.06.23
€90.00
31.03.26
-68.71%
27.08.24

Could be very worthwhile Investment >20% year
buy
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€44.20
24.06.23
€60.00
31.12.25
-83.14%
19.08.24

Could be very worthwhile Investment >20% year
buy
Syros Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.68
24.06.23
€4.00
31.12.25
36.94%
01.10.23

Could be very worthwhile Investment >20% year
buy
NVIDIA Corp.

Start price
Target price
Perf. (%)
€38.80
24.06.23
€100.00
31.12.27
10.31%
02.12.23

Could be very worthwhile Investment >20% year
buy
NVIDIA Corp.

Start price
Target price
Perf. (%)
€38.80
24.06.23
€100.00
31.12.27
10.31%
02.12.23

Could be very worthwhile Investment >20% year
buy
NVIDIA Corp.

Start price
Target price
Perf. (%)
€38.80
24.06.23
€100.00
31.12.27
10.31%
02.12.23

Could be very worthwhile Investment >20% year
buy
Viking Therapeutics Inc

Start price
Target price
Perf. (%)
€18.54
24.06.23
€27.00
31.12.25
347.68%
03.03.24

Could be very worthwhile Investment >20% year
buy
Voyager Therapeutics Inc

Start price
Target price
Perf. (%)
€10.60
24.06.23
€20.00
31.12.25
-43.30%
22.08.24

Could be very worthwhile Investment >20% year
buy
Protagonist Therapeutics Inc

Start price
Target price
Perf. (%)
€21.80
24.06.23
€40.00
31.12.25
-
31.08.23

Could be very worthwhile Investment >20% year
buy
Makita Corp.

Start price
Target price
Perf. (%)
€25.75
24.06.23
-
24.06.24
-4.08%
18.03.24

buy
Makita Corp.

Start price
Target price
Perf. (%)
€25.75
24.06.23
-
24.06.24
-4.08%
18.03.24

buy
Makita Corp.

Start price
Target price
Perf. (%)
€25.75
24.06.23
-
24.06.24
-4.08%
18.03.24

buy
Apple Inc.

Start price
Target price
Perf. (%)
€171.66
23.06.23
-
23.07.23
-0.30%
26.06.23

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Apple Inc.

Start price
Target price
Perf. (%)
€171.66
23.06.23
-
23.07.23
-0.30%
26.06.23

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
buy
Apple Inc.

Start price
Target price
Perf. (%)
€171.66
23.06.23
-
23.07.23
-0.30%
26.06.23

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected